SHANGHAI, April 21, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Administration (JFDA). The inspection covered two denosumab injections: 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). The facility was granted conclusion of “Compliance” from JFDA. This marks Mabwell’s inaugural recognition by a regulatory authority in a PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) member country.
As an authoritative international organization for pharmaceutical GMP inspections worldwide, PIC/S is committed to harmonizing inspection standards and strengthening international cooperation. As a PIC/S member, Jordan’s GMP standards are aligned with high-level international regulatory requirements. The inspection provided a comprehensive and systematic review of Taizhou Mabwell’s facilities and equipment, quality systems, production, warehousing, testing, and batch release processes, earning high praise and recognition from the auditors.
To date, Mabwell has reached strategic collaborations covering 33 countries for its denosumab injection products, submitted marketing applications in 8 countries, and obtained marketing approval in Pakistan in 2025.
Mr. Huiguo Hu, Board Member, Senior Vice President, and Board Secretary of Mabwell, said, ” Successfully passing this GMP inspection by a PIC/S member country demonstrates that Mabwell’s quality management system is gaining increasing recognition from high-standard overseas regulatory authorities, which will help accelerate the registration and marketing process for our products in more countries. At the same time, this represents significant progress for us in the Middle East region, further enhancing the accessibility of high-quality biologics locally and benefiting more patients.”
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
